What is the typical demographic for acne inversa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Demographic Profile of Acne Inversa (Hidradenitis Suppurativa)

Acne inversa (hidradenitis suppurativa) primarily affects young adults, with typical onset in the second to fourth decades of life, and has a female predominance (3:1, F:M ratio). 1

Prevalence and Distribution

  • Prevalence is estimated at approximately 1-4% in the UK population, with European studies consistently reporting around 1% prevalence in the general population 1
  • US studies using health claims databases suggest a lower prevalence of 0.05%, likely due to underdiagnosis and methodological limitations 1
  • The disease typically presents after puberty with painful, deep-seated inflammatory lesions in apocrine gland-bearing areas 1
  • Mean age of onset is between 20-30 years, though early onset (before age 13) has been reported in some cases and is associated with stronger genetic susceptibility and more widespread disease 1

Gender and Racial Distribution

  • Female predominance is well-established with a 3:1 female to male ratio 1
  • Higher prevalence has been documented among African-American and biracial individuals, with 3-fold and 2-fold greater prevalence respectively compared to white individuals 1
  • The disproportionate prevalence in women and Black patients intensifies the need for early identification and management 1

Associated Risk Factors

  • Strong association with obesity, with an odds ratio of 33 compared to controls 1
  • Significant association with smoking, with an odds ratio of 36 compared to controls 1
  • However, non-smoking patients with normal BMI are also seen in clinical practice 1

Common Comorbidities

  • Higher overall comorbidity burden compared to both healthy populations and psoriasis patients 1
  • Nearly doubled risk of cardiovascular-associated death compared to controls 1
  • Associated with type 2 diabetes, hyperlipidemia, and hypertension 1
  • Increased risk of depression and completed suicide, likely related to the chronic, painful nature of the disease and its impact on quality of life 1
  • Association with inflammatory bowel disease, particularly Crohn's disease (but not ulcerative colitis) 1
  • Higher prevalence of other follicular occlusion disorders:
    • Acne vulgaris/conglobata (4.5-15.2% prevalence) 1
    • Dissecting cellulitis of the scalp (9.2% prevalence) 1
    • Pilonidal disease (1.4-2.3% prevalence) 1
    • Pyoderma gangrenosum (0.2-0.4% prevalence) 1

Clinical Presentation

  • Presents with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas 1
  • Most commonly affects axillae, inguinal and anogenital regions 1
  • May present with comedones (characteristically paired), papules, pustules, nodules, cysts, abscesses, sinus tracts, and fistulae in flexural areas 1
  • Causes severe pain, pruritus, chronic discharge, and persistent malodor 1
  • Long-standing disease can result in fibrosis, dermal contractures, scarring, and reduced mobility 1

Impact on Quality of Life

  • Has the highest impact on patients' quality of life among all assessed dermatological diseases 2
  • Can lead to social withdrawal, stigmatization, unemployment, and suicidal thoughts 3
  • Significantly impairs sexual life of affected individuals 3

Key Diagnostic Considerations

  • Diagnosis requires typical lesions (painful nodules, abscesses, sinus tracts, bridged scars, or open comedones) in typical sites, with chronic and recurrent presentation 1
  • Disease severity is often measured using the Hurley staging system (I-III) 1
  • Often diagnosed after long delays, highlighting the need for increased awareness 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2015

Research

[Acne inversa/hidradenitis suppurativa: An update].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.